PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.73%
EBIT growth 50-75% of TRVN's 14.78%. Martin Whitman would suspect suboptimal resource allocation.
2.45%
Operating income growth under 50% of TRVN's 14.78%. Michael Burry would be concerned about deeper cost or sales issues.
10.71%
Net income growth at 50-75% of TRVN's 14.41%. Martin Whitman would question fundamental disadvantages in expenses or demand.
23.59%
EPS growth at 50-75% of TRVN's 42.50%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
23.59%
Diluted EPS growth at 50-75% of TRVN's 42.50%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
16.70%
Share reduction more than 1.5x TRVN's 48.87%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
16.70%
Diluted share reduction more than 1.5x TRVN's 48.87%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-19.06%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-18.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42182.97%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-53680.51%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-38238.10%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-21634.42%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-19064.37%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-68658.62%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-3403.93%
Negative equity/share CAGR over 10 years while TRVN stands at 88865.27%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-569.70%
Negative 5Y equity/share growth while TRVN is at 88865.27%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-664.70%
Negative 3Y equity/share growth while TRVN is at 88865.27%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
Negative asset growth while TRVN invests at 46.49%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-169.45%
We have a declining book value while TRVN shows 3.70%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
6.82%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-13.19%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.